about
Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapyEffectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysisConcomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions.Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditionsComparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs.Comparison of NNRTIs in antiretroviral-naïve patients.No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trialChanges in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL studyCost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adultsThe PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mLSevere nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature.Treatment of advanced HIV infection.Shedding of plasma membrane proteins.Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapyEfavirenz: enhancing the gold standard.Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations.Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction].The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens.A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals.Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting.Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature.Causes and consequences of incomplete HIV RNA suppression in clinical trials.Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).The future of antiretroviral therapy: challenges and needs.Protease inhibitor monotherapy.Protease inhibitor monotherapy and the CNS: peace of mind?Updating our understanding of pulmonary disease associated with HIV infection.Protease inhibitor monotherapy: what is its role?Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).Executive summary of the consensus document on the management of renal disease in HIV-infected patients.Consensus document on the management of renal disease in HIV-infected patients.Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial.Assessment of second-line antiretroviral regimens for HIV therapy in Africa.Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma
P50
Q28534903-984D70A5-A465-4C91-A33E-CF8B58A844F2Q28742423-8B18E2D7-1346-4AD6-A930-1969389E5109Q31046396-E9971575-976C-44B2-91D1-5415340D0177Q33321334-587C4639-A7FD-414B-8268-EF89F043E205Q33897898-BD3304AB-80A8-4CBA-9C5B-E04C5B188BEFQ33980117-3C86A93A-BBDB-4C04-A33F-39DB525CD1C1Q34041782-44DF1DD9-DB99-4FD4-951D-01730954047DQ34394202-E78F73D7-5D8A-420A-A33B-5FCCE7AA69EBQ34450075-5C3C903B-80B3-45F1-8549-23B52442803CQ34474894-2E47A52D-FBED-43ED-A791-997CE762FF81Q34474905-2CF61361-C741-4328-AD77-CFDFEAD5F4ACQ34475120-D6BBC2F9-A300-4FB9-ACB8-97FB610DB1CEQ34535751-90A4B812-C71B-4054-BD7C-03FE6FFA38F4Q35058322-4CAA5748-B2C4-4645-9489-0412DAAB6E88Q35107607-7E75B05C-CEE6-44D3-AEC3-EE999159A8CFQ35158051-6AB980AD-9B80-421B-AF1F-011055ACD949Q35583696-4B19938C-D274-47F1-AE77-6B5E6BD6A137Q35625995-4C8C079E-AB4C-48F3-B91B-17D8C2F8D8C6Q35635844-AB16EAE4-EC67-4549-8F92-955BB631A55AQ35677256-596BEF22-9C1A-474D-9AF0-A31CDD85C618Q35849801-7E77AA4B-2070-485D-A7E6-2ED412E532CFQ36293999-59B77D9F-EFC6-4E9B-97C6-A54D80EE2F8AQ36722728-4E6A3531-0AA3-4D34-BA88-5B2FAE40DD9AQ36892885-2863C724-8AED-47AD-8E97-DF9FDC413365Q37590956-B7A3966E-52F2-4E13-B57B-DD041C0598E6Q37631282-A69D6600-A269-431F-9FAA-B507CC46ED38Q37667804-3B7EC0EA-42E1-42C5-886E-2A635B987C9BQ37708892-114DB74F-38F7-4214-9A36-E19E825FB073Q37819920-8C5ACA03-02D6-4397-BFBF-531572639A1FQ37889512-17F97E1C-69E1-4F69-B3A2-23A7897301C8Q37976919-5BC42301-28E0-4F08-B489-DDF452BD4C0DQ37987855-0D4A0FD2-9AFD-44BB-85A9-E2E5CE91D0A4Q38225483-4B555A0C-F798-4C91-918F-93191FDDA291Q38270322-AAA21716-58E4-4672-86FA-B596E08139CAQ38281715-068F3610-007F-460D-8E5A-D465DA873E51Q38442904-882BD15F-F377-4484-AB79-262006FEE440Q38861912-50B5E818-DAA5-4886-95FF-49D6ACDEBD31Q39216531-891EA1F1-E776-4915-AA2B-D7E8EC891A8CQ39515202-0F3FD19A-1A18-4592-8A0C-D5DCA26D404EQ40007917-D4AFEE63-4DFA-4176-8978-25477F411344
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jose R Arribas
@es
Jose R Arribas
@nl
Jose R Arribas
@sl
Jose R. Arribas
@en
type
label
Jose R Arribas
@es
Jose R Arribas
@nl
Jose R Arribas
@sl
Jose R. Arribas
@en
altLabel
Jose R Arribas
@en
prefLabel
Jose R Arribas
@es
Jose R Arribas
@nl
Jose R Arribas
@sl
Jose R. Arribas
@en
P1053
A-1595-2015
P106
P21
P31
P3829
P496
0000-0002-7410-9450